Table 2 Clinical characteristics of patients stratified according to metastasis* and HER2 status.
From: Vitamin D3 reduces the expression of M1 and M2 macrophage markers in breast cancer patients
Parameter | Nonmetastatic (N0M0) | LN-metastatic (N + M0) | P | Distant-metastatic (M1) | P vs. N0M0 | P vs. N + M0 | HER2− | HER2+ | P | |
|---|---|---|---|---|---|---|---|---|---|---|
Age | N | 88 | 32 | 11 | 39 | 81 | ||||
(years) | 59.5 (31–85) | 60 (36–83) | > 0.999 | 66 (38–75) | 0.959 | > 0.999 | 57 (44–83) | 63 (31–85) | 0.516 | |
BMI | N | 84 | 31 | 11 | 38 | 76 | ||||
(kg/m2) | 26.8 (16.5–42.5) | 26.8 (20.0–39.5) | > 0.999 | 25.4 (19.6–28.7) | > 0.999 | 0.605 | 27.9 (16.5–40.4) | 26.6 (17.2–42.5) | 0.202 | |
25(OH)D3 | N | 88 | 32 | 10 | 39 | 81 | ||||
(ng/mL) | 23.3 (2–67.7) | 23.6 (7.14–60.1) | > 0.999 | 26.3 (9.7–39.6) | > 0.999 | > 0.999 | 21.5 (7.14–67.7) | 23.7 (2–60.1) | 0.868 | |
FSH | N | 88 | 31 | 9 | 39 | 80 | ||||
(mIU/mL) | 60.8 (2.4–154) | 54.8 (6.2–105) | > 0.999 | 59.8 (2.1–96.9) | > 0.999 | > 0.999 | 65 (3.3–112) | 56.4 (2.4–154) | 0.348 | |
Estradiol | N | 88 | 32 | 10 | 39 | 81 | ||||
(pg/mL) | 14 (4–574) | 16.5 (4–617) | > 0.999 | 11 (4–135) | > 0.999 | > 0.999 | 14 (4–390) | 13 (4–617) | 0.882 | |
PTH | N | 88 | 32 | 7 | 39 | 81 | ||||
(pg/mL) | 29.9 (18–230) | 31.2 (18.5–57.4) | > 0.999 | 38.6 (4.6–48.2) | > 0.999 | > 0.999 | 34.2 (18.5–91.3) | 29.6 (18–79.4) | 0.090 | |
